Trial Profile
Acceptability study of a new paediatric formulation of Orphacol (cholic acid) in paediatric patients treated for inborn errors in primary bile acid synthesis due to 3ß-Hydroxy-5-C27- steroid oxidoreductase deficiency or 4-3-Oxosteroid-5ß-reductase deficiency-ORPH-PAED-01
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Jul 2018
Price :
$35
*
At a glance
- Drugs Cholic acid (Primary)
- Indications Inborn genetic disorders; Liver disorders
- Focus Therapeutic Use
- Acronyms ORPH-PAED-01
- 30 Jul 2018 Status changed from active, no longer recruiting to completed.
- 22 Jun 2018 New trial record